(MedPage Today) -- The FDA granted accelerated approval to the first cereblon E3 ligase modulation (CELMoD) therapy for relapsed or refractory multiple myeloma, the agency announced on Thursday.
(MedPage Today) -- The FDA granted accelerated approval to the first cereblon E3 ligase modulation (CELMoD) therapy for relapsed or refractory multiple myeloma, the agency announced on Thursday.